OBJECTIVES: To develop a murine model of viral rhinosinusitis. STUDY DESIGN: Randomized, controlled, animal model. METHODS: Mice were intranasally inoculated with Sendai virus (SeV) or ultraviolet (UV)-inactivated virus. On days 3 and 10 postinfection, nasal lavage fluid was obtained for viral culture. On days 4, 10, and 38 postinfection, sinus mucosa was harvested and analyzed by flow cytometry for CD3-, CD4-, CD8-, CD25-, CD11b-, CCR3-, and GR1-positive cells. Nasal hyperresponsiveness to histamine challenge was measured on days 8 and 36 postinoculation. RESULTS: On day 3, viral cultures were positive from all SeV-inoculated mice but from none of the UV-inactivated mice (P<or=.0039). There was no growth of virus from either group on day 10. On day 4, flow cytometry on SeV-infected sinus cells showed a significant increase in macrophages (P<or=.03) and neutrophils (P<or=.02) compared with controls. This inflammation resolved by day 10. On day 38, mice inoculated with SeV had significantly more CD8+ (P<or=.044) and CD4+CD25+ (P<or=.017) cells than did controls. On day 8, there was a significant increase in both sneezing (P<or=.002) and nasal rubbing (P<or=.002) in the SeV-infected group to histamine challenge compared with controls. This difference continued to day 36. CONCLUSIONS: Inoculation with SeV results in an acute infection that resolves spontaneously within 10 days. Infected mice develop a significant increase in T-suppressor and T-regulatory cells after resolution of the acute infection, which persists for at least 38 days. The persistence of these T cells is associated with hyperresponsiveness to histamine. This mouse model has some parallels to chronic rhinosinusitis after a viral infection in humans and should allow us to clarify the pathophysiology of this disease.
OBJECTIVES: To develop a murine model of viral rhinosinusitis. STUDY DESIGN: Randomized, controlled, animal model. METHODS:Mice were intranasally inoculated with Sendai virus (SeV) or ultraviolet (UV)-inactivated virus. On days 3 and 10 postinfection, nasal lavage fluid was obtained for viral culture. On days 4, 10, and 38 postinfection, sinus mucosa was harvested and analyzed by flow cytometry for CD3-, CD4-, CD8-, CD25-, CD11b-, CCR3-, and GR1-positive cells. Nasal hyperresponsiveness to histamine challenge was measured on days 8 and 36 postinoculation. RESULTS: On day 3, viral cultures were positive from all SeV-inoculated mice but from none of the UV-inactivated mice (P<or=.0039). There was no growth of virus from either group on day 10. On day 4, flow cytometry on SeV-infected sinus cells showed a significant increase in macrophages (P<or=.03) and neutrophils (P<or=.02) compared with controls. This inflammation resolved by day 10. On day 38, mice inoculated with SeV had significantly more CD8+ (P<or=.044) and CD4+CD25+ (P<or=.017) cells than did controls. On day 8, there was a significant increase in both sneezing (P<or=.002) and nasal rubbing (P<or=.002) in the SeV-infected group to histamine challenge compared with controls. This difference continued to day 36. CONCLUSIONS: Inoculation with SeV results in an acute infection that resolves spontaneously within 10 days. Infected mice develop a significant increase in T-suppressor and T-regulatory cells after resolution of the acute infection, which persists for at least 38 days. The persistence of these T cells is associated with hyperresponsiveness to histamine. This mouse model has some parallels to chronic rhinosinusitis after a viral infection in humans and should allow us to clarify the pathophysiology of this disease.
Authors: Gye Song Cho; Byung-Jae Moon; Bong-Jae Lee; Chang-Hoon Gong; Nam Hee Kim; You-Sun Kim; Hun Sik Kim; Yong Ju Jang Journal: J Clin Microbiol Date: 2013-01-16 Impact factor: 5.948
Authors: M Elizabeth Brockson; Laura A Novotny; Joseph A Jurcisek; Glen McGillivary; Martha R Bowers; Lauren O Bakaletz Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240
Authors: Michael B Soyka; David Holzmann; Tomasz M Basinski; Marcin Wawrzyniak; Christina Bannert; Simone Bürgler; Tunc Akkoc; Angela Treis; Beate Rückert; Mübeccel Akdis; Cezmi A Akdis; Thomas Eiwegger Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Jae Woong Hwang; Ki Jeong Lee; In Hak Choi; Hye Min Han; Tae Hoon Kim; Sang Hag Lee Journal: J Allergy Clin Immunol Date: 2019-08-23 Impact factor: 10.793